Note 20 - Commitments
|12 Months Ended|
Mar. 31, 2020
|Notes to Financial Statements|
|Commitments and Contingencies Disclosure [Text Block]||
Research and development contracts and contract research organizations agreements:
The Corporation utilizes contract manufacturing organizations related to the development and production of clinical material and clinical research organizations to perform services related to the Corporation’s clinical trials. Pursuant to these agreements with manufacturing and contract research organizations, the Corporation has the right to terminate the agreements either without penalties or under certain penalty conditions. There are
nopenalties to be incurred in any open contracts.
RKO Supply Agreement:
October 25, 2019,the Corporation signed a supply agreement with Aker Biomarine Antartic AS (”
Aker”), to purchase raw krill oil product (RKO) for a committed volume of commercial starting material for CaPre for a total value of
$3.1million (take or pay). The delivery of the product has been established following a calendar year basis and it must be completed in the
4thcalendar quarter of
March 31, 2020,the remaining balance of the commitment with Aker amounts to
The entire disclosure for commitments and contingencies.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef